Clinical Trial Update: Safety and Efficacy Study of OPC-415 in Patients With Relapsed and/or Refractory Multiple Myeloma [Phase 1, Phase 2]

View source ↗

Summary

Safety and efficacy study of OPC-415 in relapsed or refractory multiple myeloma is in Phase 1/2. The trial is currently ACTIVE_NOT_RECRUITING and sponsored by O…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• OPC-415

Snippet

Sponsor: Otsuka Pharmaceutical Co., Ltd. | Conditions: Multiple Myeloma (MM) | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING